A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopenia (ITP)

Recruiting

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(8 sites)

Italy

Gaslini Children's Hospital, Genova

Poland

Uniwersytecki Szpital Dzieciecy w Lublinie, Lublin

Romania

Institutul Clinic Fundeni, Bucharest

Spain

Hospital Universitari Vall d'Hebron, Barcelona

Hospital Sant Joan de Deu Barcelona, Esplugues de Llobregat